Hims & Hers Stops Selling Compounded Weight-Loss Pill After FDA Warning

Hims & Hers has decided to stop offering its compounded semaglutide weight-loss pill. This decision came after the U.S. Food and Drug Administration (FDA) said it would take action against the company. Semaglutide is the ingredient in Wegovy, a popular weight-loss drug.

The telehealth company had launched the pill for $49, but removed it from its services just two days later. The move also followed threats of legal action from Novo Nordisk, the maker of Wegovy.

Hims & Hers' pill was described as a copycat version of Wegovy. The FDA has been closely watching companies that offer compounded or 'knockoff' versions of approved drugs.

The company stopped after the FDA warned it would take action against offering a compounded version of semaglutide, which is the active ingredient in an approved drug.

A compounded drug is a medication made by a pharmacist by mixing ingredients to create a custom version, usually when the official version is not available or suitable for a patient.

Novo Nordisk makes the approved version, called Wegovy.

No, the pill has been removed from the company's offerings.

Reuters

Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.

CNBC

Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened legal action against the telehealth provider.

Investors Business Daily

Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.

Investors Business Daily

Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.

Business Insider

Hims & Hers introduced a once-a-day weight loss pill on Thursday. Then, on Saturday, the company said it would stop offering the pill to customers.

Reuters

Novo Nordisk's Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49 compounded weight-loss pill over the weekend, following legal threats from Novo and the U.S. Food and Drug Administration.

CNBC

Novo Nordisk, maker of Wegovy, saw its stock rise 8% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its plan to sell a copycat weight-loss pill.

Market Watch

Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk's Wegovy oral weight-loss drug.

CNBC International TV

Hims & Hers has said it will stop selling its discounted version of Novo Nordisk's weight-loss pill Wegovy, boosting the stock in European trade.

WSJ

The telehealth provider said it would no longer offer access to a compounded version of Wegovy after Novo Nordisk had threatened legal action.

Barrons

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.

Forbes

Faced with legal action, Hims and Hers walked back on its plans to launch the cheaper drug in an announcement Saturday. The company said: “Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry.

CNBC

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the feud between Novo and Hims, which said on Saturday it will stop offering its newly launched obesity...

Seeking Alpha

Hims & Hers Health (HIMS) drops 15% premarket after halting compounded Wegovy pill sales amid FDA scrutiny and Novo Nordisk pressure. Samsung (SSNLF) surges on imminent HBM4 chip mass production, reportedly shipping to Nvidia for next-gen AI accelerators.

Reuters

Novo Nordisk said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers for infringing on the Danish group's patents.

CNBC Television

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.

Proactive Investors

Hims & Hers scraps low-cost weight-loss pill following backlash Him & Hers (NYSE:HIMS) shares are set to open 23% lower at about $18 after the telehealth company announced over the weekend that it will stop offering a compounded oral version of semaglutide, the active ingredient in Novo Nordisk's we...

Bloomberg Markets and Finance

Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloomberg's Sam Fazeli reports.

Benzinga

Novo Nordisk A/S (NYSE: NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE: HIMS) for infringing U.S. Patent 8,129,343 with Hims' compounded semaglutide products for the U.S. market.

Invezz

Novo Nordisk's Denmark-listed shares climbed more than 7%, while the stock gained close to 6% in US premarket trading after telehealth company Hims & Hers said it would stop offering its newly launched oral obesity pill copycat following regulatory scrutiny. Hims & Hers, by contrast, fell nearly 20%...

CNBC Television

Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. CNBC's Brandon Gomez has the details.

Schwab Network

Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.

Fast Company

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss med...

Investors Business Daily

Hims stock crashed Monday after Novo Nordisk filed a lawsuit, claiming the online pharmacy is "deceiving patients" with its compounded drugs.

The Motley Fool

Hims & Hers Health announced it will sell Ozempic lookalike pills for $49 a month last week. The FDA objected Friday, and Novo Nordisk sued for patent infringement this morning.

Investopedia

Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.

The Motley Fool

Hims & Hers advertised a $49 Wegovy lookalike pill Thursday -- then on Saturday said it won't sell it. Both the FDA and Novo Nordisk have objected to what Hims & Hers is doing.

Benzinga

Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty.

WSJ

The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.

Schaeffers Research

Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a...

The Motley Fool

On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved by the agency. Last week, Hims & Hers announced plans to offer a copycat GLP-1 pill at a lower price point than Novo Nordisk, which is also suing Hims &...

Seeking Alpha

Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are forecast at only 30% of 2025 revenue, with a broader focus on preventative care and platform growth. Rec...

Forbes

There are two words that can cause a stock to plummet quicker than one can utter semaglutide: FDA warning. This is precisely what transpired with Hims & Hers Health Inc's shares, as Hims & Hers stock (NYSE: HIMS) dropped approximately 34% over the past month due to investor panic triggered by regula...

Reuters

Novo Nordisk's U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish pharmaceutical drugmaker's campaign against companies selling compounded versions of its blockbuster weight-loss drug Wegovy.

Zacks Investment Research

NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.

Seeking Alpha

Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitly called out Hims. Hims launched, then halted, an oral compounded semaglutide pill ($49) after two d...

Show All Sources